Cargando…
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127283/ https://www.ncbi.nlm.nih.gov/pubmed/30190469 http://dx.doi.org/10.1038/s41408-018-0122-3 |
_version_ | 1783353443465822208 |
---|---|
author | Ottmann, Oliver Saglio, Giuseppe Apperley, Jane F. Arthur, Christopher Bullorsky, Eduardo Charbonnier, Aude Dipersio, John F. Kantarjian, Hagop Khoury, Hanna Jean Kim, Dong-Wook Healey, Diane Strauss, Lewis Cortes, Jorge E. |
author_facet | Ottmann, Oliver Saglio, Giuseppe Apperley, Jane F. Arthur, Christopher Bullorsky, Eduardo Charbonnier, Aude Dipersio, John F. Kantarjian, Hagop Khoury, Hanna Jean Kim, Dong-Wook Healey, Diane Strauss, Lewis Cortes, Jorge E. |
author_sort | Ottmann, Oliver |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-6127283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61272832018-09-07 Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib Ottmann, Oliver Saglio, Giuseppe Apperley, Jane F. Arthur, Christopher Bullorsky, Eduardo Charbonnier, Aude Dipersio, John F. Kantarjian, Hagop Khoury, Hanna Jean Kim, Dong-Wook Healey, Diane Strauss, Lewis Cortes, Jorge E. Blood Cancer J Correspondence Nature Publishing Group UK 2018-09-03 /pmc/articles/PMC6127283/ /pubmed/30190469 http://dx.doi.org/10.1038/s41408-018-0122-3 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Correspondence Ottmann, Oliver Saglio, Giuseppe Apperley, Jane F. Arthur, Christopher Bullorsky, Eduardo Charbonnier, Aude Dipersio, John F. Kantarjian, Hagop Khoury, Hanna Jean Kim, Dong-Wook Healey, Diane Strauss, Lewis Cortes, Jorge E. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib |
title | Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib |
title_full | Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib |
title_fullStr | Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib |
title_full_unstemmed | Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib |
title_short | Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib |
title_sort | long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127283/ https://www.ncbi.nlm.nih.gov/pubmed/30190469 http://dx.doi.org/10.1038/s41408-018-0122-3 |
work_keys_str_mv | AT ottmannoliver longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT sagliogiuseppe longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT apperleyjanef longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT arthurchristopher longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT bullorskyeduardo longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT charbonnieraude longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT dipersiojohnf longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT kantarjianhagop longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT khouryhannajean longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT kimdongwook longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT healeydiane longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT strausslewis longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib AT cortesjorgee longtermefficacyandsafetyofdasatinibinpatientswithchronicmyeloidleukemiainacceleratedphasewhoareresistanttoorintolerantofimatinib |